Drug Search Results
More Filters [+]

Dalfopristin

Alternative Names: dalfopristin, synercid
Latest Update: 2023-09-13
Latest Update Note: News Article

Product Description

Mechanisms of Action: PR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Canada | Germany | Ireland | Italy | New Zealand | Portugal | South Africa | Sweden | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dalfopristin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events